Navigation Links
Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence

Aromatase Inhibitors drug, Femara given after 5 years of Tamoxifen therapy is found to give protection against occurrence of Breast cancer recurrence. Breast cancer is the second leading cause of cancer// in women. Breast cancer mostly occurs in post menopausal women and various risk factors are attributed for the occurrence of breast cancer.

Treatment of breast cancer initially involves removal of the entire breast or part of the breast with the cancer lump followed by Radiation therapy and Chemotherapy. Cytotoxic drugs are given as chemotherapy for patients with breast cancer; usually 6 cycles of chemotherapeutic drugs are given such as Cyclophosphamide, 5 flurouracil, adiramycin. After these procedures 5 years of Tamoxifen therapy is recommended for post menopausal women. Tamoxifen therapy is recommended only for 5 years as studies in which tamoxifen given for more than 5 years shows no difference. Tamoxifen acts as an anti-estrogen by which it competitively inhibits the estrogens produced by the body, as estrogen is used up by the cancer cell for its growth and production. Metastasis and recurrence occurs in some cancer patients, though the chance of metastasis is very less as only 1 in 10000 cells has the capacity to reach the blood stream and cause cancer in a new organ.

Recurrence mostly occurs due to pitfalls or not properly taking therapy or tablets, even tamoxifen resistance developed by the patient may also lead to recurrence. Recurrence may occur at the same initial cancer site called as loco-regional or in a new site.

The new study using Femara Aromatase Inhibitors after 5 years of Tamoxifen therapy as found to give protection against occurrence of recurrence. Aromatase inhibitors lower the levels of estrogen in the body by acting on the Aromatase enzyme involved in making estrogen. The study was conducted in 5000 postmenopausal women who have finished their 5 years tamoxifen therapy and they were given femara for an other 5 years. Though the overall survival rates of both the group were same, the group taking femara had a significant lower risk of breast cancer recurrence. The patients with lymph node positive cancer had a significant better survival rate taking femara. Though femara had some side effects such as osteoporosis in 8.1 %, hot flashes in 58 % and hair loss, and these side effects are very common and less significant compared to its benefits.
'"/>




Related medicine news :

1. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
2. Early Switch to an Aromatase Inhibitor Increases Survival
3. LipB Protein Inhibitors Help To Fight Against TB
4. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
5. ACE Inhibitors For Vascular Disease Patients
6. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Thyroid hormone treatment hastens recovery after cardiac surgery
9. Morning after pill effective up to five days after having unprotected sex
10. Liver donors can thrive after transplant
11. Recouping blood flow after a stroke
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... , ... January 17, 2017 , ... ... and the Montclair State University’s Athletic Training Education program forged a relationship built ... Training Education Program, which is consists of both student members and certified ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide comfort ... leader in the fast-casual category, announces a hearty and wholesome Winter Menu. Starting ... Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken ...
(Date:1/16/2017)... Battle Creek, MI (PRWEB) , ... January 17, 2017 , ... ... substance abuse located in Southwest Michigan, joined other volunteers and organizations in support of ... sees hundreds of children and families dressed up in colorful costumes of all designs ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... California Southern ... Beazley has served on CalSouthern’s Board of Trustees and as a core faculty member, ... he has been a professor of psychology at Pepperdine University, where he earned his ...
(Date:1/16/2017)... , ... January 16, 2017 , ... Gym Source, America’s ... a new showroom in East Hanover, New Jersey. , “We are elated to be ... new innovative in-store concept is designed to give clients a seamless and motivating shopping ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 - First major agreements signed with ... expected to grow by a CAGR of approximately 6-9% between ... company which operates globally across a number of sectors, announces that ... notable successes and is well-positioned for further expansion within the rapidly ... ...
(Date:1/17/2017)... , Jan. 17, 2017  Allergan Plc (NYSE: ... from Venus II, the second of two pivotal phase III ... in women with abnormal bleeding due to uterine fibroids.  A ... the second half of 2017. "We are pleased ... and safety profile of ulipristal acetate as shown in our ...
(Date:1/16/2017)... Research and Markets has announced the addition of the "Global ... ... drugs market to grow at a CAGR of 9.19% during the ... and the growth prospects of the global multiple myeloma drugs market ... revenue generated from the sales of branded and generic drugs used ...
Breaking Medicine Technology: